Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06392932 · ClinicalTrials.gov registry record · NA
Esophageal Temperature During PVI Using Q-DOT Micro
A NA study of Atrial Fibrillation Paroxysmal, sponsored by Cedars-Sinai Medical Center.
- Recruiting
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT06392932: Recruiting NA study of Atrial Fibrillation Paroxysmal, sponsored by Cedars-Sinai Medical Center.
NCT06392932 is a NA study of Atrial Fibrillation Paroxysmal that is actively recruiting participants, run by Cedars-Sinai Medical Center. The registered enrollment target is 30 participants, below the 182-participant average among 4 other Atrial Fibrillation Paroxysmal trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06392932, a NA study of Atrial Fibrillation Paroxysmal, is actively recruiting participants, sponsored by Cedars-Sinai Medical Center.
- RECRUITING
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will assess how two different ablation strategies, using two different ablation catheters during catheter ablation for paroxysmal atrial fibrillation, affect the temperature of the esophagus during ablation, and the risk of injury to the esophagus.
Conditions Studied
Interventions
- DEVICE QDOT Micro ablation catheter
- DEVICE ST SF ablation catheter
Study Locations (1)
California
- Cedars-Sinai Smidt Heart Institute - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2024-10-04 |
| Est. Completion | 2027-03 |
| Phase | NA |
What NCT06392932 shows while recruiting
NCT06392932 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 182-participant average among 4 other Atrial Fibrillation Paroxysmal trials with a reported enrollment target (84% lower).
The record links to 1 condition, with Atrial Fibrillation Paroxysmal appearing as the primary indexed condition, and to 2 interventions - of which QDOT Micro ablation catheter is the first listed.
NCT06392932 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06392932 about?
NCT06392932 is a clinical study titled "Esophageal Temperature During PVI Using Q-DOT Micro". This study will assess how two different ablation strategies, using two different ablation catheters during catheter ablation for paroxysmal atrial fibrillation, affect the temperature of the esophagus during ablation, and the risk of injury to the esophagus.
What is the current status of trial NCT06392932?
This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2024-10-04. Estimated completion is 2027-03.
What conditions does trial NCT06392932 study?
This clinical trial studies the following conditions: Atrial Fibrillation Paroxysmal.
What interventions are being tested in trial NCT06392932?
The interventions under investigation include: QDOT Micro ablation catheter (DEVICE), ST SF ablation catheter (DEVICE).
Who is sponsoring clinical trial NCT06392932?
This trial is sponsored by Cedars-Sinai Medical Center, which has 339 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06392932 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atrial Fibrillation Paroxysmal
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Full-Avoidance vs. Permissive/Regulated Drinking & Outcomes On Fibrillation
RECRUITING · NA
-
RESOLVE-AF: Clinical Evaluation of the Ablacath™ Mapping Catheter and Ablamap® System Utilizing Electrographic Flow (EGF) Mapping to Resolve Extra-PV Sources of Atrial Fibrillation and Guide Ablation Therapy.
ACTIVE NOT RECRUITING · NA
-
RiLuzole to Reduce Atrial FIb Study Using Holter Monitoring
RECRUITING · Phase 2
-
Assert-IQ Implantable Cardiac Monitor (ICM) Post Market Study
ACTIVE NOT RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI